An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)
2
Issued Date
2022-11-01
Resource Type
ISSN
16006135
eISSN
16006143
Scopus ID
2-s2.0-85134726248
Pubmed ID
35841235
Journal Title
American Journal of Transplantation
Volume
22
Issue
11
Start Page
2651
End Page
2660
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Transplantation Vol.22 No.11 (2022) , 2651-2660
Suggested Citation
Bruminhent J., Setthaudom C., Phornkittikorn P., Chaumdee P., Prasongtanakij S., Srisala S., Malathum K., Boongird S., Nongnuch A., Assanatham M., Nakgul L., Sanmeema N., Phuphuakrat A., Kiertiburanakul S. An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study). American Journal of Transplantation Vol.22 No.11 (2022) , 2651-2660. 2660. doi:10.1111/ajt.17151 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85433
Title
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)
Author's Affiliation
Other Contributor(s)
Abstract
Immunogenicity following an additional dose of Coronavirus disease 2019 (COVID-19) vaccine was investigated in an extended primary series among kidney transplant (KT) recipients. Eighty-five KT participants were randomized to receive either an mRNA (M group; n = 43) or viral vector (V group; n = 42) vaccine. Among them, 62% were male, with a median (IQR) age of 50 (43–59) years and post-transplantation duration of 46 (26–82) months. At 2 weeks post-additional dose, there was no difference in the seroconversion rate between the M and V groups (70% vs. 65%, p =.63). A median (IQR) of anti-RBD antibody level was not statistically different between the M group compared with the V group (51.8 [5.1–591] vs. 28.5 [2.9–119.3] BAU/ml, p =.18). Furthermore, the percentage of participants with positive SARS-CoV-2 surrogate virus neutralization test results was not statistically different between groups (20% vs. 15%, p =.40). S1-specific T cell and RBD-specific B cell responses were also comparable between the M and V groups (230 [41–420] vs. 268 [118–510], p =.65 and 2 [0–10] vs. 2 [0–13] spot-forming units/106 peripheral blood mononuclear cells, p =.60). In conclusion, compared with an additional dose of viral vector COVID-19 vaccine, a dose of mRNA COVID-19 vaccine did not elicit significantly different responses in KT recipients, regarding either humoral or cell-mediated immunity. (TCTR20211102003).